Skip to content

XORTX
  • About
    • Management Team
    • Board of Directors
    • Advisory Board
  • Pipeline
    • Coronavirus – COVID-19 Program
    • Autosomal Dominant Polycystic Kidney Disease
    • Diabetic Nephropathy
  • Strategic Partnerships
  • Investors
    • Press Releases
    • Presentations
    • Media
    • Independent Research
    • Financials
    • SEDAR
    • Transfer Agent
    • Upcoming Events
  • Contact
Site Search

XORTX Announces Appointment of CFO

  • November 6, 2018December 22, 2020
  • by aaronbb

CALGARY, Alberta, Nov. 06, 2018 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE:XRX; OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease (“PKD”), is pleased to announce the appointment of James Fairbairn as Chief Financial Officer.  James Fairbairn has more than 20 years of experience with publicly-traded companies.  He is a Chartered Professional Accountant, having obtained his CPA designation in 1987 and an Institute-certified Director.  Jim Fairbairn holds a B.A. from the University of Western Ontario.   

Dr. Allen Davidoff, XORTX’s CEO stated, “We are pleased to have Jim join XORTX. His extensive corporate governance and financial reporting experience with emerging companies will be an asset for the Company.  We wish to thank Dave Matthews for his commitment to XORTX and excellent work during the time he was part of the team. We wish him all the best success in his future endeavors.  Dave is remaining with XORTX to assist with the transition.”

In connection with his appointment as Chief Financial Officer, James Fairbairn has been granted 250,000 options to purchase common shares of the Company exercisable at a price of $0.50 per common share and expiring five years from the date of grant, being November 5, 2023.

About XORTX Therapeutics Inc.

XORTX biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease.  XORTX has lead programs to develop treatments for progressive kidney disease due to diabetes, diabetic nephropathy and polycystic kidney disease.  Secondary programs focus on developing therapies for health consequences that accompany pre-diabetes, diabetes and cardiovascular disease. Additional information on XORTX is available at www.xortx.com.

For further information, please contact:

Allen Davidoff, CEO

adavidoff@xortx.com or +1 403 455 7727

or Erik Matthews, Corporate Communications & Investor Relations

info@xortx.com or +1 747 203 5240

The CSE has neither approved nor disapproved the contents of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to share on Google+ (Opens in new window)

Related

XORTX Announces Revision to Polycystic Kidney Disease Clinical Development Plan
XORTX Receives FDA Response on Orphan Drug Designation Application

Press Releases

  • XORTX Announces Notice to Grant European Patent April 6, 2021
  • XORTX to Present at “Zoom With LD MICRO” March 16, 2021
  • XORTX to Present and Participate in the Sachs 14th Annual European Life Sciences CEO Forum 2021 March 9, 2021
  • XORTX Files New Provisional Patent to Treat and Protect Individuals Most at Risk to Severe Viral Infection March 8, 2021
  • XORTX Confirms $1 Million in Warrant Exercise Proceeds March 2, 2021

Archives

  • 2012 Press Releases 3
  • 2014 Press Releases 2
  • 2015 Press Releases 1
  • 2017 Press Releases 2
XORTX Therapeutics Inc.
4000, 421 7th Avenue SW
Calgary, Alberta T2P 4K9
Ph: +1 (403) 455-7727
info@xortx.com
Theme by Colorlib Powered by WordPress